Unveiling Elevance Health (ELV) Q4 Outlook: Wall Street Estimates for Key Metrics

Zacks
01-17

Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $3.82 per share in its upcoming release, pointing to a year-over-year decline of 32%. It is anticipated that revenues will amount to $44.67 billion, exhibiting an increase of 5.2% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

That said, let's delve into the average estimates of some Elevance Health metrics that Wall Street analysts commonly model and monitor.

It is projected by analysts that the 'Revenues- Premiums' will reach $36.61 billion. The estimate points to a change of +4.2% from the year-ago quarter.

The average prediction of analysts places 'Revenues- Service fees' at $2.09 billion. The estimate suggests a change of +8.6% year over year.

The consensus among analysts is that 'Revenues- Net investment income' will reach $532.37 million. The estimate indicates a change of +0.6% from the prior-year quarter.

Analysts predict that the 'Revenues- Product revenue' will reach $5.94 billion. The estimate suggests a change of +10.2% year over year.

Analysts expect 'Medical Membership - Total' to come in at 45.98 million. The estimate is in contrast to the year-ago figure of 46.96 million.

Based on the collective assessment of analysts, 'Medical Membership - Medicare - Medicare Advantage' should arrive at 2.05 million. The estimate compares to the year-ago value of 2.05 million.

The consensus estimate for 'Medical Membership - Medicaid' stands at 9.06 million. The estimate compares to the year-ago value of 10.5 million.

Analysts forecast 'Medical Membership - Federal Employees Health Benefits' to reach 1.66 million. Compared to the present estimate, the company reported 1.64 million in the same quarter last year.

The collective assessment of analysts points to an estimated 'Medical Membership - Total Medicare' of 2.94 million. Compared to the present estimate, the company reported 2.97 million in the same quarter last year.

Analysts' assessment points toward 'Medical Membership - Commercial Risk-Based - Individual' reaching 1.32 million. Compared to the current estimate, the company reported 1.03 million in the same quarter of the previous year.

The combined assessment of analysts suggests that 'Benefit Expense Ratio' will likely reach 92.4%. Compared to the current estimate, the company reported 89.2% in the same quarter of the previous year.

According to the collective judgment of analysts, 'Medical Membership - Commercial Fee-Based' should come in at 27.33 million. The estimate is in contrast to the year-ago figure of 27.07 million.

View all Key Company Metrics for Elevance Health here>>>

Shares of Elevance Health have experienced a change of +5.1% in the past month compared to the -2.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ELV is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Elevance Health, Inc. (ELV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10